Parameter
| Biomarker | PD-L1 (Tumor cell) | Full name | Programmed Death-Ligand 1 | Molecular Type | Protein |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Prognosis and prediction of immune therapy response |
| Disease | TGCT | Disease Subtypes | / | ||
| Organ | Testis | Test Sample / Technology Platform | Tumor tissue (immunohistochemistry) | ||
| Pathobiological Mechanisms | Combining PD-1 inhibition with T cell activity to mediate immune evasion. | ||||
| Clinical Availability Status | Stage of research | ||||
| Notes and Dynamics | Highly expressed in choriocarcinoma; associated with poor prognosis; limited response to immunotherapy. | ||||